- Home
- GORO vs MIST Comparison
GORO vs MIST Comparison
Compare GORO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GORO | MIST |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.5M | 138.2M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GORO | MIST |
|---|---|---|
| Price | $2.83 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.63 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.99 | $2,915.14 |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $70.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $1.00 |
| 52 Week High | $4.00 | $3.06 |
Technical Indicators
Market Signals| Indicator | GORO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 66.13 | 43.49 |
| Support Level | $0.84 | $1.01 |
| Resistance Level | $4.00 | $1.42 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 78.45 | 37.50 |
Price Performance
Historical ComparisonAbout GORO Gold Resource Corporation
Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.